Novel Molecules

One of SkyBio’s main objectives is to design and test novel molecules based on our experience with structure-function relationships and structural predictions of existing commercial drugs and their interaction with neurotoxic protein aggregates. We have defined the structural determinants for antiaggregant properties and are working in collaboration with experts in chemical synthesis in order to obtain different families of compounds that inhibit the reversal of this toxic aggregation.